Janssen posts Phase 3 ExPEC9V vaccine results; registers two guselkumab IBD studies
Janssen Research & Development posted Phase 3 vaccine results while Janssen-Cilag registered two observational guselkumab studies in Crohn's disease and ulcerative colitis.
Janssen's registry activity this period spanned a completed Phase 3 vaccine trial with new results and two newly listed observational studies in inflammatory bowel disease.
- ExPEC9V (JNJ-78901563), Phase 3, for prevention of invasive extraintestinal pathogenic E. coli disease in adults 60 and older with a prior urinary tract infection: results were first posted on 2026-09-28. The study is designed to show whether the vaccine works better than placebo at preventing a first invasive E. coli disease event caused by the vaccine's target O-serotypes.1 The trial enrolled 17797 participants.1
- Guselkumab (Tremfya), observational study, for moderate-to-severe Crohn's disease and ulcerative colitis: the GALILEO study (NCT07848737) was first posted on 2026-09-30 and is not yet recruiting. The study aims to track how long participants with moderate-to-severe Crohn's disease and ulcerative colitis stay on guselkumab treatment in routine clinical practice.2 Lead sponsor is Janssen-Cilag, S.A., with an estimated enrollment of 200 participants and an estimated start date of 2026-10-30.2
- Guselkumab (Tremfya), observational study, for moderate-to-severe Crohn's disease and ulcerative colitis: the GLAMOUR study (NCT07851207) was first posted on 2026-10-01 and is not yet recruiting. The study is meant to describe participants with Crohn's disease and ulcerative colitis receiving guselkumab outside a clinical trial, looking at how well they stay on treatment and how the drug performs in both the overall group and specific subgroups.3 Lead sponsor is Janssen-Cilag Ltd., with an estimated enrollment of 200 participants and an estimated start date of 2026-10-05.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.